Activation of the AKT and mammalian target of rapamycin pathways and the inhibitory effects of rapamycin on those pathways in canine malignant melanoma cell lines

American Journal of Veterinary Research

Volumn 70, Issue 2, 2009, Pages 263-269

  Kent, Michael S ^a   Collins, Cameron J ^a   Ye, Fang ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL FRACTIONATION; CELL SURVIVAL; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; ENZYME ACTIVATION; MELANOMA CELL; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; DOGS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SIROLIMUS; STATISTICS, NONPARAMETRIC; TUMOR STEM CELL ASSAY;

CANIS FAMILIARIS; MAMMALIA;

EID: 60749124741     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.70.2.263     Document Type: Article

References (35)

1. Koenig A, Bianco SR, Fosmire S, et al. Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma. Vet Pathol 2002;39:458-472.
2. Henry CJ, Brewer WG Jr, Whitley EM, et al. Canine digital tumors: a veterinary cooperative oncology group retrospective study of 64 dogs. J Vet Intern Med 2005;19:720-724.
3. Bergman PJ. Canine oral melanoma. Clin Tech Small Anim Pract 2007;22:55-60. 4 Bergman PJ, Camps-Palau MA, McKnight JA, et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 2006;24:4582-4585.
4. Rassnick KM, Ruslander DM, Cotter SM, et al. Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000). J Am Vet Med Assoc 2001;218:1444-1448.
5. Liao JC, Gregor P, Wolchok JD, et al. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun 2006;6:8.
6. Karst AM, Dai DL, Cheng JQ, et al. Role of p53 up-regulated modulator of apoptosis and phosphorylated Akt in melanoma cell growth, apoptosis, and patient survival. Cancer Res 2006;66:9221-9226.
7. Rowinsky EK. Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol 2004;16:564-575.
8. Panwalkar A, Verstovsek S, Giles FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 2004;100:657-666.
9. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001;15:807-826.
10. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996;14:483-510.
11. Janus A, Robak T, Smolewski P. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett 2005;10:479-498.
12. Vignot S, Faivre S, Aguirre D, et al. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005;16:525-537.
13. Molhoek KR, Brautigan DL, Slingluff CL Jr. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor kapamycin. J Transl Med 2005;3:39.
14. Karbowniczek M, Spittle CS, Morrison T, et al. mTOR is activated in the majority of malignant melanomas. J Invest Dermatol 2008;128:980-987.
15. Costa LJ. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma. Cancer Treat Rev 2007;33:78-84.
16. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 2004;91:1420-1424.
17. Gordon IK, Ye F, Kent MS. Evaluation of the mammalian target of rapamycin pathway and the effect of rapamycin on target expression and cellular proliferation in osteosarcoma cells from dogs. Am J Vet Res 2008;69:1079-1084.
18. Altomare DA, Testa JR. Perturbations of the ART signaling pathway in human cancer. Oncogene 2005;24:7455-7464.
19. Seguin B, Zwerdling T, McCallan JL, et al. Development of a new canine osteosarcoma cell line. Vet Comp Oncol 2006;4:232-240.
20. Choi C, Kusewitt DF. Comparison of tyrosinase-related protein-2, S-100, and Melan A immunoreactivity in canine amelanotic melanomas. Vet Pathol 2003;40:713-718.
21. Miettinen M, Fernandez M, Franssila K, et al. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers. Am J Surg Pathol 2001;25:205-211.
22. Brugarolas J, Lei K, Hurley RL, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 2004;18:2893-2904.
23. Hiratani K, Haruta T, Tani A, et al. Roles of mTOR and JNK in serine phosphorylation, translocation, and degradation of IRS-1. Biochem Biophys Res Commun 2005;335:836-842.
24. Withers DJ, Ouwens DM, Nave BT, et al. Expression, enzyme activity, and subcellular localization of mammalian target of rapamycin in insulin-responsive cells. Biochem Biophys Res Commun 1997;241:704-709.
25. Mirmohammadsadegh A, Marini A, Nambiar S, et al. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res 2006;66:6546-6552.
26. Xu G, Zhang W, Bertram P, et al. Pharmacogenomic profiling of the PI3K/ PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 2004;24:893-900.
27. Thallinger C, Werzowa J, Poeppl W, et al. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice. J Invest Dermatol 2007;127:2411-2417.
28. Collier DS, Calne R, Thiru S, et al. Rapamycin in experimental renal allografts in dogs and pigs. Transplant Proc 1990;22:1674-1675.
29. Kyles AE, Gregory CR, Craigmill AL. Comparison of the in vitro antiproliferative effects of five immunosuppressive drugs on lymphocytes in whole blood from cats. Am J Vet Res 2000;61:906-909.
30. Hartner WC, Van der Werf WJ, Lodge JP, et al. Effect of rapamycin on renal allograft survival in canine recipients treated with antilymphocyte serum, donor bone marrow and cyclosporine. Transplantation 1995;60:1347-1350.
31. Yakimets WJ, Lakey JR, Yatscoff RW, et al. Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses. Rapamycin efficacy is blood level related. Transplantation 1993;56:1293-1298.
32. Ochiai T, Gunji Y, Nagata M, et al. Effects of rapamycin in experimental organ allografting. Transplantation 1993;56:15-19.
33. Whiteman EL, Cho H, Birnbaum MJ. Role of Akt/protein kinase B in metabolism. Trends Endocrinol Metab 2002;13:444-451.
34. Tsang CK, Qi H, Liu LF, et al. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 2007;12:112-124.
35. Zhang JF, Liu JJ, Lu MQ, et al. Rapamycin inhibits cell growth by induction of apoptosis on hepatocellular carcinoma cells in vitro. Transpl Immunol 2007;17:162-168.